<DOC>
	<DOCNO>NCT01365585</DOCNO>
	<brief_summary>The objective observational study gain clinical insight actual use sildenafil citrate ( Revatio™ ) treatment pulmonary arterial hypertension ( PAH ) . The primary objective ass effectiveness safety sildenafil dose ≥20mg three time daily treatment PAH .</brief_summary>
	<brief_title>Evaluate The Clinical Effectiveness , Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension</brief_title>
	<detailed_description>The study design propose retrospective chart review go back five year ( 01 April 2006 estimate ) time study initiation ( 31 March 2011 estimate ) . Within five-year period , study index occur first time adult patient begin sildenafil treatment PAH period least three month . The patient take sildenafil dos ≥ 20mg tid treatment PAH .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Patients must least 18 year age study index ; Patients must diagnosis PAH . PAH conventionally define mean pulmonary arterial pressure ( PAP ) &gt; 25 mmHg pulmonary capillary wedge pressure ( PCWP ) ≤ 15 mmHg pulmonary vascular resistance ( PVR ) ≥ 240 dynes/s/cm5 right heart catheterization ; Patients must initiate sildenafil treatment PAH ; dose ≥ 20 mg tid within 5 year prior study initiation Patient know contraindication sildenafil study index ; Patient participate investigational study sildenafil treatment PAH period begin 6 month prior study index</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pulmonary arterial hypertension</keyword>
	<keyword>sildenafil citrate</keyword>
	<keyword>Revatio</keyword>
</DOC>